Chest ACCP Education Calendar
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
doi:10.1378/chest.06-3087
(Chest. 2007; 132:998-1006)
© 2007 American College of Chest Physicians
This Article
Right arrow Full Text Free
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (2)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Patel, N. M.
Right arrow Articles by Kawut, S. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Patel, N. M.
Right arrow Articles by Kawut, S. M.
Related Content
Right arrow Recent Advances in Chest Medicine

Pulmonary Hypertension in Idiopathic Pulmonary Fibrosis*

Nina M. Patel, MD; David J. Lederer, MD, MS; Alain C. Borczuk, MD and Steven M. Kawut, MD, MS, FCCP

* From the Departments of Medicine (Dr. Patel) and Pathology (Dr. Borczuk), College of Physicians and Surgeons, and the Department of Medicine (Drs. Lederer and Kawut), College of Physicians and Surgeons, Joseph L. Mailman School of Public Health, Columbia University, New York, NY.

Correspondence to: Nina M. Patel, MD, Division of Pulmonary, Allergy & Critical Care, Columbia University, 622 W 168th St, PH 8 East, Room 101, New York, NY 10032; e-mail: np2199{at}columbia.edu

Abstract

Idiopathic pulmonary fibrosis (IPF) is an untreatable diffuse parenchymal lung disease with a median survival of < 3 years. Pulmonary hypertension (PH) is frequently seen in patients with IPF and is commonly attributed to hypoxic vasoconstriction and capillary destruction. Pathology findings include endothelial proliferation and medial hypertrophy that exceed those expected in the setting of hypoxia. Noninvasive evaluation has limited sensitivity and specificity for the diagnosis of PH in IPF; therefore, right-heart catheterization remains the "gold standard" diagnostic test. PH in patients with IPF is associated with decreased exercise capacity and worse survival. Given the grave consequences of this condition, treatment of PH could improve functional outcomes and survival. However, possible treatments such as long-term supplemental oxygen and targeted vascular therapy are either unstudied or remain unproven.

Key Words: idiopathic pulmonary fibrosis • pulmonary artery pressure • pulmonary hypertension • 6-min walk test




This article has been cited by other articles:


Home page
 ChestHome page
D. A. Zisman, A. S. Karlamangla, S. M. Kawut, O. A. Shlobin, R. Saggar, D. J. Ross, M. I. Schwarz, J. A. Belperio, A. Ardehali, J. P. Lynch III, et al.
Validation of a Method To Screen for Pulmonary Hypertension in Advanced Idiopathic Pulmonary Fibrosis
Chest, March 1, 2008; 133(3): 640 - 645.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by the American College of Chest Physicians.